the sensitivity of glioblastoma to current
therapies. © 2022 The Authors
Shnayder, N.A.,
Novitsky, M.A.,
Neznanov, N.G.,
Limankin, O.V.,
Asadullin, A.R.,
Petrov, A.V.,
Dmitrenko, D.V.,
Narodova, E.A.,
Popenko, N.V.,
Nasyrova, R.F. (2022) and clinical predictors and a personalized
therapy strategy for schizophrenia. However, it should be recognized
Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) of which is influenced by modifying factors (APs’ dose, duration of APs
therapy,
APs polytherapy
Lu, Enzhou,
Gareev, Ilgiz,
Yuan, Chao,
Liang, Yanchao,
Sun, Jingxian,
Chen, Xin,
Beylerli, Ozal,
Sufianov, Albert,
Zhao, Shiguang,
Yang, Guang (2022) and
therapies that can improve the sensitivity of gliomas to platinum drugs. © 2022 Bentham Science Publishers